BECTON, DICKINSON AND COMPANY (BDX) FY2024 Annual P&L / Income Statement

Revenue by Business Segment

2023-10-01 to 2024-09-30

Swipe to see the full flow
BECTON, DICKINSON AND COMPANY (BDX) FY2024 Annual P&L / Income StatementIncome statement for 2023-10-01 through 2024-09-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETMedicalLife SciencesInterventionalRevenuesRevenue before reconciliation (calculated)Corporate and All OtherGross profit (calculated)Cost of products soldOperating IncomeOperating expenses (calculated)Selling and administrative expenseResearch and development expenseIntegration, restructuring and transaction expenseOther operating expense (income), netIncome from Continuing Operations Before Income TaxesOther income (expense), net (calculated)Net IncomeIncome tax provisionRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$20.25 BIncome from Continuing Operations Before Income TaxesIncome from ContinuingOperations BeforeIncome Taxes$2.01 BGross profit (calculated)Gross profit(calculated)$9.13 BRevenuesRevenues$20.18 BOperating IncomeOperating Income$2.40 BNet IncomeNet Income$1.71 BMedicalMedical$10.07 BOperating expenses (calculated)Operating expenses(calculated)$6.73 BIncome tax provisionIncome taxes$300.00 MOther income (expense), net (calculated)Other income,net (calculated)−$392.00 MSelling and administrative expenseSelling and administrative expense$4.86 BCost of products soldCost of products sold$11.05 BLife SciencesLife Sciences$5.19 BResearch and development expenseResearch anddevelopment expense$1.19 BInterventionalInterventional$4.98 BIntegration, restructuring and transaction expenseIntegration, restructuringand transaction expense$458.00 MOther operating expense (income), netOther operatingexpense (income), net$222.00 MCorporate and All OtherCorporate and All Other−$67.00 M
Chart details

BECTON, DICKINSON AND COMPANY (BDX) FY2024 Annual P&L / Income Statement

Income statement for 2023-10-01 through 2024-09-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues
20,178,000,000 US dollars
Cost of products sold
11,053,000,000 US dollars
Gross profit (calculated)
9,125,000,000 US dollars
Operating expenses (calculated)
6,727,000,000 US dollars
Operating Income
2,397,000,000 US dollars
Other income (expense), net (calculated)
negative 392,000,000 US dollars
Income from Continuing Operations Before Income Taxes
2,005,000,000 US dollars
Income tax provision
300,000,000 US dollars
Net Income
1,705,000,000 US dollars
Medical
10,074,000,000 US dollars
Life Sciences
5,191,000,000 US dollars
Interventional
4,980,000,000 US dollars
Selling and administrative expense
4,857,000,000 US dollars
Research and development expense
1,190,000,000 US dollars
Integration, restructuring and transaction expense
458,000,000 US dollars
Other operating expense (income), net
222,000,000 US dollars
Revenue before reconciliation (calculated)
20,245,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Corporate and All Other
negative 67,000,000 US dollars. Reported reconciliation to consolidated revenue.
(Loss) Income from Discontinued Operations, Net of Tax
0 US dollars. Reported below-tax contribution to net income.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
  • The amounts that make up operating profit come to $2,398.00 M and operating profit is $2,397.00 M; the $1.00 M difference is within the rounding of the filed amounts.
BECTON, DICKINSON AND COMPANY (BDX) FY2024 Annual P&L / Income Statement Sankey chart, Business segment view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

45.2%

Gross profit / revenue

Operating margin

11.9%

Operating profit / revenue

Cash conversion

225.5%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!